• Torq (TORQ) has initiated phase II drilling at the Margarita Iron-Oxide-Copper-Gold Project in Chile
  • Drilling is targeting a new discovery of 90 m of 0.94-per-cent copper and 0.84 g/t gold from phase I drilling
  • The company intends to drill for 4,000 m along a 1 km trend corresponding to the discovery’s mineralization
  • CEO Shawn Wallace joined Sabrina Cuthbert to discuss the ongoing follow-up drill program
  • Torq is a Vancouver-based copper and gold exploration company with a portfolio of premium holdings in Chile
  • Torq (TORQ) is unchanged trading at $0.53 per share

Torq (TORQ) has initiated phase II drilling at the Margarita Iron-Oxide-Copper-Gold Project in Chile.

Drilling is targeting a new discovery of 90 m of 0.94-per-cent copper and 0.84 g/t gold (22MAR-013R) from phase I drilling along the Falla 13 structural corridor.

Torq intends to drill for 4,000 m along 1 km of Falla 13 exhibiting geochemical and geophysical signatures corresponding to the mineralization in 22MAR-013R.

The company believes it has a strong probability of expanding the discovery and outlining a large-scale copper-gold deposit.

It plans to pursue a number of high-quality targets similar to the Falla 13 discovery in phase III drilling.

CEO Shawn Wallace joined Sabrina Cuthbert to discuss the ongoing follow-up drill program.

Torq is a Vancouver-based copper and gold exploration company with a portfolio of premium holdings in Chile.

Torq (TORQ) is unchanged trading at $0.53 per share as of 12:13 pm EST.

More From The Market Online
The Market Online Video

Exploration company provides project portfolio update

Banyan Gold Corp. (TSXV:BYN) is focused on exploration and advancing and de-risking its AurMac Gold Project in the Yukon.
stock market down

@ the Bell: Industrials weakness snaps TSX win streak

Industrials led decliners, followed by financials, to snap the TSX’s five-day win streak while energy, utilities and mining provided gains.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.